Advertisement

Topics

Latest "Alnara Pharmaceuticals" News Stories

18:04 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "Alnara Pharmaceuticals" found in our extensive news archives from over 250 global news sources.

More Information about Alnara Pharmaceuticals on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Alnara Pharmaceuticals for you to read. Along with our medical data and news we also list Alnara Pharmaceuticals Clinical Trials, which are updated daily. BioPortfolio also has a large database of Alnara Pharmaceuticals Companies for you to search.

Showing "Alnara Pharmaceuticals" News Articles 1–25 of 10,000+

Tuesday 13th November 2018

ConSynance Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryConSynance Therapeutics Inc ConSynance Therapeutics, formerly Concerted Therapeutics Inc is a drug discovery company that concentrates on the development of new therapeutic solutions for unmet medical needs. The company provides pipeline programs such as CSTI100, CSTI200, and CSTI300, among others. It develops pipeline programs for nonalcoholic steatohepatitis and inflammatory bowel disease...


Global and Asia Androstenedione Market Status and Future Forecast 20132023 [Report Updated: 20082018] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPart 3:Asia Market by company, Type, Application RegionPart 410:Key Regions of Asia Market by Type, ApplicationPart 11:Company information, Sales, Cost, Margin etc.Part 12:ConclusionMarket Segment as fo...

Cases of measles nearly quadruple since last year in UK http://bit.ly/2QE4uvv  #measles #MMR #vaccines #Pharmaceuticals

Cases of measles nearly quadruple since last year in UK http://bit.ly/2QE4uvv  #measles #MMR #vaccines #Pharmaceuticals


Enzymatica AB ENZY Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryEnzymatica AB Enzymatica is a life science company that develops and markets medical products for various virus and bacterial infections. The company offers mouth sprays and veterinary products. Its veterinary products comprise dental health and skin relief enzyme based gels, dental and dental spray gels, spray dermal and dermal gels, and others. Enzymatica's mouth spray products are based ...

Sernova Corp SVA Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12102018] Prices from USD $250

SummarySernova Corp Sernova is a clinical stage regenerative medicines company which develops and commercializes medical device and combination products for the treatment of chronic diseases. The company develops Cell Pouch System, an implantable medical device, which offers a natural organlike environment for the long term survival and function of insulin producing islets for the treatment of dia...

Enanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis

EXPEDITION-8 is the first Phase 3b study evaluating 8 weeks of MAVYRET™ in treatment-naïve chronic hepatitis C virus (HCV)-infected patients with compensated cirrhosis across all major genotypes (GT1-6)1 In cohort one, 100 percent of genotype 1, 2, 4, 5 and 6 treatment-naïve chronic HCV patients with compensated cirrhosis ...

Gem Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27092018] Prices from USD $250

SummaryGem Pharmaceuticals LLC Gem Pharmaceuticals is a clinicalstage biopharmaceutical company that develops proprietary anthracycline derivatives. The company's pipeline products include GPX150 for oncology, topical GPX150 for inflammation, GPX 150 oral formulations and potency analogues programs, and noncardiotoxic versions of other anthracyclines. It uses proprietary chemical modification plat...

Glenmark expands manufacturing to US in ‘natural choice’ North Carolina

India-headquartered Glenmark Pharmaceuticals has opened a 100,000-square-foot facility on the East Coast for the manufacture of fixed dose formulations.

Catabasis Pharmaceuticals, Inc. (CATB) CEO Jill Milne on Q3 2018 Results - Earnings Call Transcript

Vernalis Research, a Ligand Company, Achieves Success Milestones in Collaboration with Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017. The research utilizes Vernalis' fragment and structure-based drug discovery platform for two undisclosed oncology targets. A...

Masy BioServices Leases 60,000 SF at Pepperell Place

Continued Growth Creates Need for More Biostorage Space PEPPERELL, Mass. (PRWEB) November 13, 2018 In one of the biggest commercial leases in the Nashoba region this year, Masy BioServices, the largest employer in Pepperell, Mass., has increased its leased space at Pepperell Place to 60,000 square feet. The 35 year old company operates two other locations in town plus a facility in Pennsylvania. ...

Biomm SA BIOM3 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryBiomm SA Biomm, formerly Savicevic Participacoes SA is a biopharmaceutical company that research, develops, produces and markets biomedicines. The company develops processes for the production of active pharmaceutical ingredients and enzymes used in the production of biofuels. It licenses its technology to companies interested in producing insulin. Biomm's technology is used for the product...

Catabasis Pharmaceuticals Reports Third Quarter 2018 Financial Results and Reviews Business Progress

-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Underway and Starting Enrollment -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2018, and reviewed recent business progress.

Ferring Pharmaceuticals Enters Exclusive Agreement with INVO Bioscience to Commercialize the Novel INVOcell™ System for Use in the Treatment of Infertility

The INVOcell intravaginal culture (IVC) device uses a woman’s own body as a natural incubator during fertilization and early embryo development Ferring aims to help increase access to fertility treatment by making the INVOcell IVC system a widely available option for women and their healthcare providers F...

Ginkgo BioWorks Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 27082018] Prices from USD $250

SummaryGinkgo BioWorks Inc Ginkgo BioWorks is a biotechnology company. It offers automated organism engineering, enzyme discovery and cultured fragrances. The company produces ingredients through fermentation with engineered yeasts for perfumes, foods, cosmetics markets. It uses laboratory automation synthesis, software and automation, and high performance analytical tools to produce these product...

Catabasis Pharmaceuticals Announces Collaboration with the University of Texas Southwestern to Explore the Potential Benefits of Edasalonexent on Cardiac Function in Duchenne and Becker Muscular Dystrophies

-- One-Year Preclinical Study of Edasalonexent, a Novel Inhibitor of NF-kB, in Animal Models of Duchenne to Investigate Potential Improved Cardiac Function -- Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced a

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd 874 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummaryGuangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Guangzhou Baiyunshan Pharmaceutical is a manufacturer of herbal medicine, chemical raw material medicine and preparation, biological medicine, and health products. The company also offers herbal tea, Chinese and Western medicine, intermediates, and others. It also offers services such as research and development, and manufacturing and sale...

Ferring Pharmaceuticals Enters Exclusive Agreement with INVO Bioscience to Commercialize the ...

Read more...

The Corporate Reputation of Pharma, 2017: The Patient Perspective - Asia Edition - ...

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Pharmaceuticals Read more...

The Corporate Reputation of Pharma, 2017: The Patient Perspective - Latin America Edition - ...

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900Related Topics: Pharmaceuticals Read more...

Spectrum Pharmaceuticals Appoints Dr. Jeffrey Vacirca to its Board of Directors

Spectrum Pharmaceuticals Inc., (NASDAQ: SPPI) a biotechnology company with fully integrated commercial and drug development operations and a primary focus in hematology and oncology, today announced the appointment of Jeffrey Vacirca, MD, FACP to its Board of Directors. Dr. Vacirca is a practicing oncologist and the current president of the Commun...

SunGen Pharma LLC Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 17092018] Prices from USD $250

SummarySunGen Pharma LLC SunGen Pharmaceuticals is a speciality pharmaceutical company, which concentrates on developing, manufacturing and distributing generic products through partnership with contract manufacturing organizations CMOs. The company's product portfolio includes controlledrelease and extendedrelease oral solid tablets, capsules, lyophilized injectables, creams, ointments, patches, ...

CStone proposes IPO in Hong Kong

CStone Pharmaceuticals proposed to list an initial public offering on the Hong Kong stock exchange.  -More- 

Catabasis Pharmaceuticals 2018 Q3 - Results - Earnings Call Slides

Enable Injections Partners with UCB and Apellis Pharmaceuticals

Patient-centric drug delivery important for treatment adherence, commercial success


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks